Market Closed -
OTC Markets
15:42:26 2024-05-30 EDT
|
5-day change
|
1st Jan Change
|
0.0325
USD
|
-17.20%
|
|
+0.31%
|
+192.79%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2.896
|
3.316
|
3.242
|
15.31
|
2.452
|
0.9615
|
Enterprise Value (EV)
1 |
2.859
|
3.436
|
3.82
|
17.16
|
3.415
|
3.47
|
P/E ratio
|
131
x
|
-0.61
x
|
-1.57
x
|
-2.17
x
|
3.75
x
|
-0.56
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.72
x
|
3.16
x
|
-
|
566
x
|
49.5
x
|
58.4
x
|
EV / Revenue
|
2.68
x
|
3.27
x
|
-
|
635
x
|
69
x
|
211
x
|
EV / EBITDA
|
-13.7
x
|
-1.04
x
|
-
|
-6.79
x
|
-2.47
x
|
-8.89
x
|
EV / FCF
|
-4.1
x
|
7.14
x
|
-6.14
x
|
40.5
x
|
-1.22
x
|
-2.23
x
|
FCF Yield
|
-24.4%
|
14%
|
-16.3%
|
2.47%
|
-81.8%
|
-44.9%
|
Price to Book
|
10.5
x
|
-5.8
x
|
-3.29
x
|
-3.73
x
|
-2.14
x
|
-0.45
x
|
Nbr of stocks (in thousands)
|
4,456
|
16,654
|
27,020
|
45,047
|
75,438
|
86,624
|
Reference price
2 |
0.6498
|
0.1991
|
0.1200
|
0.3399
|
0.0325
|
0.0111
|
Announcement Date
|
4/2/19
|
5/14/20
|
4/15/21
|
4/15/22
|
4/17/23
|
4/16/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1.066
|
1.05
|
-
|
0.027
|
0.0495
|
0.0165
|
EBITDA
1 |
-0.2085
|
-3.309
|
-
|
-2.527
|
-1.382
|
-0.3904
|
EBIT
1 |
-0.2216
|
-3.322
|
-1.814
|
-2.531
|
-1.389
|
-0.3992
|
Operating Margin
|
-20.78%
|
-316.37%
|
-
|
-9,364.82%
|
-2,806.8%
|
-2,424.23%
|
Earnings before Tax (EBT)
1 |
0.021
|
-3.67
|
-1.957
|
-4.873
|
0.6536
|
-1.416
|
Net income
1 |
0.021
|
-3.67
|
-1.941
|
-4.873
|
0.6536
|
-1.416
|
Net margin
|
1.97%
|
-349.44%
|
-
|
-18,027.66%
|
1,320.43%
|
-8,598.37%
|
EPS
2 |
0.004973
|
-0.3264
|
-0.0763
|
-0.1568
|
0.008664
|
-0.0200
|
Free Cash Flow
1 |
-0.6972
|
0.4809
|
-0.6226
|
0.4241
|
-2.791
|
-1.557
|
FCF margin
|
-65.38%
|
45.8%
|
-
|
1,568.89%
|
-5,639.22%
|
-9,456.19%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/2/19
|
5/14/20
|
4/15/21
|
4/15/22
|
4/17/23
|
4/16/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
0.12
|
0.58
|
1.85
|
0.96
|
2.51
|
Net Cash position
1 |
0.04
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.0362
x
|
-
|
-0.733
x
|
-0.6969
x
|
-6.426
x
|
Free Cash Flow
1 |
-0.7
|
0.48
|
-0.62
|
0.42
|
-2.79
|
-1.56
|
ROE (net income / shareholders' equity)
|
-21.4%
|
1,093%
|
247%
|
191%
|
-24.9%
|
86.3%
|
ROA (Net income/ Total Assets)
|
-26.5%
|
-625%
|
-756%
|
-673%
|
-248%
|
-35.9%
|
Assets
1 |
-0.0792
|
0.5871
|
0.2567
|
0.7238
|
-0.2635
|
3.948
|
Book Value Per Share
2 |
0.0600
|
-0.0300
|
-0.0400
|
-0.0900
|
-0.0200
|
-0.0200
|
Cash Flow per Share
2 |
0.0200
|
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
0.04
|
-
|
0.81
|
Capex / Sales
|
-
|
-
|
-
|
133.35%
|
-
|
4,888.27%
|
Announcement Date
|
4/2/19
|
5/14/20
|
4/15/21
|
4/15/22
|
4/17/23
|
4/16/24
|
|
1st Jan change
|
Capi.
|
---|
| +192.79% | 3.13M | | +37.29% | 6.02B | | -21.28% | 4.19B | | +4.52% | 3.25B | | -18.16% | 2.87B | | -7.70% | 2.37B | | +41.50% | 1.89B | | -4.05% | 1.58B | | -15.56% | 1.54B | | -14.62% | 1.5B |
Alternative Medicine
|